VX-509

· Vertex Pharmaceuticals Incorporated

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for VX-509, covering 2009-02-19 to 2015-11-20. Get the full timeline:

Most recent: Clinical Trial Update: 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate [Phase 2]

See pricing